Phase III boost for alirocumab
October 17, 2013Sales and Marketing LDL, Regeneron, alirocumab
Sanofi and Regeneron Pharmaceuticals are celebrating some upbeat data from their investigational treatment alirocumab, which has proved adept at tackling …
Patients should ‘top up’ NHS costs
October 16, 2013Sales and Marketing Dixon, England, NHS, NICE, top up
A leading doctor believes that NHS patients must produce top up payments for treatments for non-life threatening conditions. Speaking at …
Rare disease fund scrapped by NHS England
October 16, 2013Research and Development, Sales and Marketing NHS England, fund, rare diseases
NHS England has pulled the plug on a £50 million fund to advance innovation in the investigation and treatment of …
Former FDA commissioner joins J&J
October 16, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, J&J, JJ
Johnson & Johnson has announced that ex-FDA commissioner Mark McClellan has been appointed to its Board of directors. Dr McClellan …
Johnson & Johnson posts strong Q3 results
October 16, 2013Sales and Marketing J&J, JJ, Q3, Velcade, results
Johnson & Johnson has posted a strong set of financials for the third quarter as new products from its pharma …
Novartis launches Facebook ‘retina app’
October 15, 2013Medical Communications AMD, Bayer, Lucentis, Novartis, set your sights
Novartis, the world’s biggest eye-care drugmaker, has launched a new Facebook retina app to raise awareness of retinal disease. The …
AstraZeneca pays $460m for cancer specialists
October 15, 2013Research and Development, Sales and Marketing ADC, AstraZeneca, Cancer, MedImmune, spirogen
AstraZeneca’s biologics arm MedImmune has bought cancer biotech firm Spirogen and set up a licensing deal with ADC Therapeutics for …
Billions spent on European cancer care
October 15, 2013Research and Development, Sales and Marketing Cancer, Europe, Lancet, Oxford, Pfizer
A new report has shown that cancer cost the European Union a total of €126 billion in 2009, with healthcare …
Price cut not enough for Pixuvri
October 15, 2013Sales and Marketing Cell Therapeutics, NICE, pixuvri
NICE is still saying no to Cell Therapeutics’ lymphoma drug Pixuvri, despite the firm offering a discount on the treatment’s …
Roche poised to get even bigger in biomanufacturing
October 15, 2013Manufacturing and Production Jobs, Merck, Roche, cuts
Roche plans to invest a massive 800 million Swiss francs ($882m) over the next five years to increase manufacturing capacity …
String of appointments to BIA Board
October 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BIA, appointments
The BioIndustry Association has appointed Kevin Cox, Donna Hackett, Jane Osbourn, Stephen Taylor, Patrick Verheyen and Tim Watts to its …
FDA throws Ranbaxy a manufacturing lifeline
October 15, 2013Manufacturing and Production FDA, Ranbaxy, recall
Problems have plagued Ranbaxy’s manufacturing operations in the last couple of years, but it enjoyed a bit of light relief …
Boehringer submits NSCLC pill
October 14, 2013Sales and Marketing
Boehringer Ingelheim has submitted its oral triple angiokinase inhibitor nintedanib for scrutiny by the European Medicines Agency. Nintedanib was impressive …
Trials and tribulations
October 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, eric low, myeloma, transparency
I have been chief executive of Myeloma UK since its inception 17 years ago, and its unique bedside to bench …
inVentiv Health creates two senior appointments


October 14, 2013Medical Communications, Research and Development, Sales and Marketing inVentiv Health
The comms division of inVentiv Health has appointed two 
social media veterans to expand its digital footprint. Emma D’Arcy joins …
Janssen agrees Zytiga deal
October 14, 2013Sales and Marketing AstraZeneca, Janssen, Zytiga
Janssen has agreed to co-promote its once-daily prostate cancer pill Zytiga with AstraZeneca in Japan for an undisclosed sum. A …
Vetter swells filling capacity with $100m investment
October 11, 2013Manufacturing and Production API, Vetter, sterile liquid
German contract development and manufacturing organisation (CDMO) Vetter says it is planning to invest over $100 million across its production …
Mixed tale for Pfizer psoriasis drug
October 11, 2013Sales and Marketing Enbrel, Pfizer, psoriasis, tofacitinib
Pfizer has seen its novel, oral Janus kinase (JAK) inhibitor tofacitinib turn in a mixed showing in late-stage trials in …
US shutdown affecting medical science
October 11, 2013Research and Development, Sales and Marketing FDA, Obama, Obamacare, us shutdown
American scientists and the latest Nobel Prize winners have condemned the US shutdown this week saying it is putting scientific …
Teva to axe 5,000 jobs in savings drive
October 11, 2013Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, Teva, cuts
The world’s largest generic drugmaker Teva will cut around 5,000 jobs from its global workforce as it looks to speed-up …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
